

Hetero receives approval for Daclatasvir's generic version

15 December 2015 | News | By BioSpectrum Bureau

Hetero receives approval for Daclatasvir's generic version



Hetero, one of India's leading generic pharmaceutical companies and one of the world's largest producer of anti-retroviral drugs, today announced that it has received the approval from Drug Controller General of India (DCGI) for the generic version of Daclatasvir tablets (30mg, 60mg).

The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.

This product is a generic version of Bristol-Myers Squibb's brand 'Daklinza' - approved by USFDA in July 2015.

Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment.

Research studies indicates that this drug enables the rapid decline of Hepatitis C virus.